Tessa Therapeutics completes USD 80 million funding round
Tessa Therapeutics are an international clinical stage biopharmaceutical company that focus on T cell therapy for solid tumours. The proceeds from this funding round will be used to further advance its clinical pipeline and bring new therapies, based on the Virus Specific T cell (VST) platform, into clinical trials.
Our life sciences patent team work with Tessa Therapeutics on their IP portfolio. The team includes Partners Richard Clegg and Frances Salisbury, Associate Adam Gregory and Technical Assistant Anna Mudge.